The Astaxanthin compound CDX-085, developed by Cardax, shows the ability to markedly increase the expression of the FOXO3 gene in a lab animal model.
WHO (World Health Organization) report confirms that air pollution is getting worse globally.
New research explains how synapses in the cortex expand with daytime stimulation and shrink with sleep, resetting the brain and preparing it for the next day.
MORE health and medical news delivered to your email every week:
Discovery repairs DNA, could lead to a revolutionary anti-aging drug, and assist NASA in getting their astronauts to Mars.
More than half of family doctors in Canada are still using manual devices, a dated technology that often leads to misdiagnosis.
New study reveals that lactate, a molecule produced during intense exercise, plays a key role in cancer cell formation.
Drinking tea decreases cognitive impairment risk by 50 percent and as much as 86 percent for those genetically at risk of Alzheimer's.
New research reveals that an altered methylation status in the genome may indicate that mortality is increased by up to seven times
Study finds that yoga classes accompanied by home practice lead to a significant reduction in symptoms of depression.
Study finds that older women face a 33 percent higher chance of developing diabetes if taking statins. Risk increases to 51 percent for those on high doses.
Chris D. Meletis, ND
- Registered at
- 2011-09-14 16:09:18
2012-04-29 01:23:08 - Harnessing the Power of Ashwaghanda for the brain---It supports more than the adrenals
Withania somnifera Studied for Brain Health and Cognition
Researchers found that Withania somnifera modulates Alzheimer’s disease pathology, according to a study published in February 2012. Withania somnifera (ashwagandha) is a commonly used botanical in Ayurvedic medicine for its rejuvenating and antioxidant properties and modulation of inflammatory pathways, the stress response and immune system activity.
The study used transgenic mice with accelerated Alzheimer’s disease pathology and beta-amyloid plaque deposition, which is implicated in the development of Alzheimer’s disease. The mice received Withania somnifera root extract for 30 days.
Withania somnifera administration resulted in reversal of behavioral deficits, plaque pathology and accumulation of beta-amyloid peptides in the brains of middle-aged and old mice. In addition, after seven days of Withania somnifera administration, beta-amyloid peptides were increased in the plasma and decreased in the brain, indicating increased transport of the peptides from the brain to the periphery.
Also after seven days, there was an increase in low-density lipoprotein receptor-related protein and the beta-amyloid peptide-degrading protease neprilysin in the liver and a rise in plasma soluble low-density lipoprotein receptor-related protein. After 14 to 21 days of declining beta-amyloid peptides in the brain, the researchers found an increase in the expression of low-density lipoprotein receptor-related protein in brain microvessels and neprilysin. The researchers state that this promotes clearance of brain beta-amyloid peptides.
The investigators concluded, "The remarkable therapeutic effect of Withania somnifera mediated through up-regulation of liver low-density lipoprotein receptor-related protein indicates that targeting the periphery offers a unique mechanism for beta-amyloid peptide clearance and reverses the behavioral deficits and pathology seen in Alzheimer's disease models.”
Sehgal N, et al. Proc Natl Acad Sci U S A. 2012;9:3510-5.
Together we can Change the Health of the World,
Chris D. Meletis, ND
Rate this topic:
You have submitted a rating for this topic.
Please login to post a reply.
DISCLAIMER: The informational material appearing at The World Health
Network Forum (“WHN Forum”) is for educational purposes only and is not
intended to prevent, diagnose, treat or cure disease or illness. The
posts on The World Health Network Forum are the opinion of the specific
author and are not statements of advice, opinion, or factual information
implied or expressed by or on behalf of The American Academy of
Anti-Aging Medicine (A4M), The World Health Network (WHN), or officers,
employees, or contracted agents of the aforementioned entities, none of
whom make any claims to promote, endorse, suggest, nor recommend any
informational material appearing at The WHN Forum. The American Academy
of Anti-Aging Medicine (A4M), The World Health Network (WHN), and
officers, employees, and contracted agents of the aforementioned
entities do not advocate the use of any particular healthcare protocol
or therapeutic agent, but The WHN Forum shares such informational
material available with the public. The content of posts at The WHN
Forum, including but not limited to links to other web sites, are the
expressed opinion of the original author and are in no way
representative of or endorsed by The American Academy of Anti-Aging
Medicine (A4M), The World Health Network (WHN), and officers, employees,
and contracted agents of the aforementioned entities. The WHN Forum is
provided "as is" without warranty of any kind, either expressed or
implied. You should not assume that The WHN Forum is error-free or that
it will be suitable for the particular purpose which you have in mind
when using it. In no event shall American Academy of Anti-Aging Medicine
(A4M), The World Health Network (WHN), and officers, employees, and
contracted agents of the aforementioned entities be liable for any
special, incidental, indirect or consequential damages of any kind, or
any damages whatsoever, including, without limitation, those resulting
from loss of use, data or profits, whether or not advised of the
possibility of damage, and on any theory of liability, arising out of or
in connection with the use or performance of The WHN Forum or other
documents which are referenced by or linked to The WHN Forum.